我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

糖肾康对糖尿病肾病气阴两虚血瘀证患者血清MCP-1和ICAM-1水平的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2017年03期
页码:
33-36
栏目:
临床研究
出版日期:
2017-07-17

文章信息/Info

Title:
Effects of Tangshenkang on the MCP-1, ICAM-1 of Diabetic Kidney Diseasewith Qi-Yin Eficiency and Blood Stasis Syndrome
作者:
胡顺金1杨丽2吴幽婉2王东1金华1任克军1茅燕萍1王亿平1
1. 安徽中医药大学第一附属医院,安徽 合肥 230031;2. 安徽中医药大学研究生院,安徽 合肥 230038
Author(s):
HU Shunjin1YANG Li2WU Youwan2WANG Dong1JIN Hua1REN Kejun1MAO Yanping1WANG Yiping1
1. The First Affiliated Hospital of Anhui Traditional Chinese Medicine University, Hefei 230031, China;2. Anhui Research Institute of Anhui University of Tratiditional Chinese Medicine, Hefei 230038, China
关键词:
糖肾康 糖尿病肾病 单核细胞趋化性蛋白-1 细胞间粘附分子-1
Keywords:
Tangshenkang diabeticnephropathy monocytechemotatic protein-1 intercellular cell adhesion molecule-1
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2017.03.008
文献标识码:
A
摘要:
目的 观察糖肾康对糖尿病肾病(DN)气阴两虚血瘀证患者血清单核细胞趋化性蛋白-1(MCP-1)、细胞间粘附分子-1(ICAM-1)指标的影响,研究糖肾康对其干预作用。方法 将66例Ⅲ-Ⅳ期DN气阴两虚血瘀证患者随机分为两组(治疗组33例,对照组33例),失访3例,实际完成治疗组32例和对照组31例,并设正常组20例。对照组给予常规降糖、降压治疗,治疗组在对照组基础上加用糖肾康,两组疗程均为8周。观察临床疗效、治疗前后尿白蛋白/尿肌酐(ACR)、血清MCP-1及ICAM-1水平的变化情况。结果 治疗组临床疗效优于对照组(P<0.01);治疗后两组ACR水平均降低(P<0.01),治疗组下降幅度优于对照组(P<0.01)。血清MCP-1、ICAM-1水平均较正常组显著升高(P<0.01);治疗后,治疗组和对照组均能降低MCP-1、ICAM-1水平(P<0.01),治疗组下降幅度均优于对照组(P<0.05)。结论 糖肾康可改善气阴两虚血瘀证DN患者的临床症状,减少尿蛋白,降低血清MCP-1、ICAM-1水平,从而抑制免疫炎症反应,具有保护肾脏、延缓肾脏病进程的作用。
Abstract:
Objective To observe serum MCP-1, ICAM-1 levels and the therapeutic effect of Tangshenkang granules of diabetic kidney disease with Qi-Yin eficiency and blood stasis syndrome. Methods 66 cases of patients with Qi-Yin eficiency and blood stasis syndrome were randomly divided into treatment group and control group, the actual completion of 63 cases, 32 cases in treatment group, 31 cases in the control group; and a healthy normal group of 20 cases of patients was established. Two groups of patients were given Conventional hypoglycemic and antihypertensive therapy, in addition, Tangshenkang was plused in treating at treatment group and it was used three times a day, each time blunt one bag. The course of treatment was 8 weeks. The changes of clinical efficacy, urinary albumin/ urine creatinine(ACR), serum MCP-1 and ICAM-1 levels were observed in two groups of patients. Results The total effective rate in treatment group was significantly better than the control group(P<0.01). After treatment, the levels of ACR in treatment group and control group were significantly lower(P<0.01), and the treatment group was better than control group(P<0.01). Serum MCP-1 and ICAM-1 levels were significantly higher than those of the normal group(P<0.01); after treatment, the treatment group and the control group can reduce the level of MCP-1 and ICAM-1(P<0.01), the treatment group decreased were better than the control group(P<0.05). Conclusion Tangshen can significantly improve the clinical symptoms and blood stasis in patients with DN, reduce urinary protein, serum MCP-1 and ICAM-1 levels, inhibition immune inflammatory response, can protect the kidney, delaying kidney disease course.

参考文献/References

[1] 徐登峰. 糖尿病肾病的中医研究进展[J]. 糖尿病新世界,2015,6(11):233-234.
[2] Caramori ML,Mauer M. Diabetes and nephropathy[J]. Curr Opin Nephrol Hypertens,2003,12(3):273-282.
[3] American Diabetes Association. Standards of medical care in diabetes-2013[J]. Diabetes Care,2013,36(Suppl 1):S11-66.
[4] Mogensen CE,Schmitz A,Christensen CK. Comparative renal pathophysiology relevant to IDDM and NIDDM patients[J]. Diabetes Metabol Rev,1988,4(5):453-483.
[5] KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J]. Am J Kidney Dis,2007,49(S2):12-154.
[6] 郑莜萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002:156-162.
[7] 王东,张江,王亿平. 糖肾康颗粒对糖尿病肾病气阴两虚证患者血清C反应蛋白、白介素6和白介素18的影响[J]. 陕西中医学院学报,2015,38(6):41-44.
[8] 郭文荣,李兴. 糖尿病肾病与ADPN、TGF-β1、Collagen IV、ICAM-1关系的研究进展[J]. 医学研究杂志,2015,44(6):170-173.
[9] 顾俊菲,叶山东,汪姗,等. 二甲双胍对大鼠肾小球系膜细胞核因子-κB、单核细胞趋化蛋白-1表达及合成的影响[J]. 中国糖尿病杂志,2014,22(6):565-567.
[10] Shaker OG,Sadik NA. Transforming growth factor beta1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy[J]. Hum Exp Toxicol,2013,32(10):1089-1096.
[11] 管凌志. 2型糖尿病肾病患者血清MCP-1、NF-κB水平变化及临床意义[J]. 局解手术学杂志,2014,23(4):398-400.
[12] Volker V. The proximal tubule in the pathophysiology of the diabetic kidney[J]. Am J Physiol Regul Integr Comp Physiol,2011,300(5):1009-1022.
[13] 周旭. 不同分期糖尿病肾病患者尿液IL-18、MCP-1水平变化的研究[J]. 中国医药指南,2015,13(30):78.
[14] 蒋姗姗,龙艳,苏珂,等. T2DM合并慢性肾脏疾病患者血清MCP-1变化及其临床意义[J]. 重庆医学,2015,44(27):3827-3829.
[15] Utsumi K,Kawabe M,Hirama A,et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1,VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis[J]. Clin Chim Acta,2007,377(1-2):198-200.
[16] Wang L,Zhang L,Yu Y,et al. The protective effects of taurine against early renal injury in STZ-induced diabetic rats,correlated with inhibition of renal LOX-1-mediated ICAM-1 expression[J]. Ren Fail,2008,30(8):763-771.
[17] 孟凡东,李伟. 利拉鲁肽抑制高糖诱导大鼠肾小球系膜细胞系TNF-α和ICAM-1表达[J]. 基础医学与临床,2012,32(12):1426-1430.
[18] 吕勇,王亿平,曹恩泽,等. 糖肾康颗粒对糖尿病肾病肾损害实验指标影响的研究[J]. 新中医,2006,38(2):44-45.
[19] 曹恩泽,余新颖,胡顺金,等. 糖肾康对实验性糖尿病大鼠早期肾脏病变的作用[J]. 中国中西医结合肾病杂志,2002,3(8):448-450.
[20] 刘玲,王东,魏玲,等. 糖肾康颗粒对糖尿病肾病气阴两虚、瘀血阻络证患者血清胱抑素C及尿纤维连接蛋白的干预作用[J]. 安徽中医药大学学报,2014,33(2):29-32.

备注/Memo

备注/Memo:
* 基金项目: 安徽省卫生厅中医药科研计划课题(2012ZY12)
收稿日期: 2017 - 06- 16
作者简介: 胡顺金(1963-),男,安徽巢湖人,主任医师,研究方向:中西医结合治疗慢性肾脏病,E-mail:565839441@qq.com
更新日期/Last Update: 2017-06-20